Newly-released Cancer Biopsy Market analysis report by Future Market Insights shows that global sales of the Cancer Biopsy Market in 2022 were held at US$ 22.2 Billion. With a CAGR of 18%, the projected market growth from 2023 to 2033 is expected to be higher than the historical growth. The Tissue Biopsies type is expected to be the highest revenue-generating segment, accounting for a CAGR of nearly 19% from 2023 to 2033.
| Attribute | Details |
|---|---|
| Global Cancer Biopsy Market (2023) | US$ 25.5 Billion |
| Global Cancer Biopsy Market (2033) | US$ 131.4 Billion |
| Global Cancer Biopsy Market CAGR (2023 to 2033) | 18% |
| USA Cancer Biopsy Market CAGR (2023 to 2033) | 21.4% |
| Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Cancer Biopsy Market industry research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value increased at around 13.9% CAGR, wherein, countries such as the USA, United Kingdom, China, Japan, and South Korea held a significant share in the global market.
The increasing elderly populace, along with the rise in instances of cancer diagnoses, is fueling growth in the cancer clinical market. Also, the effective and less costly use of liquid biopsy procedures and increasing biopsy appointees are all expected to impact the market growth.
Some of today's prominent procedures in medical diagnosis include endoscopic, arthroscopic, bone marrow, skin, needle, and surgical biopsies. Needle biopsies are regarded as a trusted method for the early detection of patients suffering from these methods. However, fine-needle aspiration needle biopsies, which have been found to be less invasive and faster, are aiding the increase in popularity of the slice.
People have much higher rates of cancer nowadays not just because of medical problems like blood pressure and substance abuse, but also because of environmental causes, use of tobacco, biological irrevocable factors, and changes in lifestyle. Cancer is the second biggest cause of death worldwide as a result of contagious viral agents, chemical exposures, toxins, poor environmental factors, substance abuse, and lifestyle choices.
The IARC estimates that by 2020 the worldwide burden of disease due to cancer is projected to be 19.3 million cases and 9.96 million deaths worldwide. A liquid biopsy entails reduced expense, earlier prognosis, therapy surveillance, identification of tumor heterogeneity, acquired drug resistance, and patient comfort compared to conventional diagnostic tools for handling cancer.
Principal Consultant
During the forecast period, the market in North America is projected to account for a significant share, with the USA playing a large role in regional revenue. Consequently, effective methods that the US government and its agencies have found are extensively used, permitting liquid biopsies to be developed for use in new states across the nation.
The FDA for quick-sampling practices implements regulatory strategies based on the USA. The recommendations and the approval precedents for specially generated biomarkers, companion diagnostics, and provisional categories of fit under this framework are steps toward the completion of the CLIA-related advancement of liquid biopsy regulatory channels. The incremental success of FDA approval for the Clinical Laboratory Improvement Amendment (CLIA) has included the advancement of liquid biopsy regulatory channels.
With the growing number of breast cancer patients in Asia-Pacific, increased awareness of breast cancer liquid biopsy procedures, growth in the area of in-depth research and development in breast cancer testing, and improved health-related policies as well as the adoption of breast cancer liquid biopsy, companies are seeing lucrative opportunities for their presence in the region.
Breast cancer liquid biopsy reagent kits have the highest demand and are increasingly seen as less invasive. Market growth is also being driven by manufacturers' business development efforts in emerging economies, including in Asia-Pacific, where they are attempting to achieve a higher share of the world's fugitive liquid biopsy product market.
Biotech businesses in South Korea market cancer DNA biopsy, which allows for early detection, precise treatment, and prognostic evaluation. In the future, the market is planning to depend more on genetic mutations that lead to cancer. Growth in this sector is contingent on raising the popularity of such businesses. In the future term, client interactions and fresh research are likely to fuel market expansion.
The market in the USA is expected to reach a market size of US$ 57 Million by 2033. The market in the country is expected to swell at a CAGR of 21.4% from 2023 to 2033, with an absolute dollar opportunity of US$ 49 Million.
The market in the United Kingdom is expected to reach a valuation of US$ 4.1 Billion by 2033. Growing with a CAGR of 15.7% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of US$ 3.1 Billion.
In Japan, the market is expected to grow at a CAGR of 19.4% from 2023 to 2033, reaching US$ 6.2 Billion by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 5.1 Billion during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Tissue biopsies are still regarded as a mainstay of biopsies and are widely used in cancer diagnosis applications. The rigorous research procedures that assisted the progression of this market can be attributed to the effective testing of its products.
Advancements aimed at improving tissue biopsy processes are projected to keep the tissue biopsy segment in the lead over the next few years. Cernostics, for example, is working on an assay that can be used to diagnose cancer patients with Barrett's Esophagus.
This one-of-a-kind diagnostic test uses digitally scanned biopsy pictures to aid in the identification and quantification of changes occurring at the cellular or molecular level within a tissue. The tissue biopsies segmental market is expected to develop due to increased acceptance of this form of biopsy due to its high accuracy and low risk of harm.
According to USA breast cancer statistics, about one in every eight women in the USA develops invasive breast cancer. Year the USA in 2020, an estimated 276,480 new instances of invasive breast cancer will be identified in women, with more than 40,000 new cases of non-invasive breast cancer.
Microscopic analysis of breast tissue is necessary to diagnose cancer or ascertain the tone and type, which is happening more due to the rise in diagnoses. Thanks to the increase in individuals with cancer, the need for needle or surgical biopsies to acquire tissue for analysis has increased, contributing to market growth.
Key companies are helping to drive market expansion by diversifying their diagnostics portfolios and increasing the adoption of their own biopsy tools.
Key recent developments of key players in the Cancer Biopsy Market are as follows:
Similarly, recent developments related to companies in the Cancer Biopsy Market have been tracked by the team at Future Market Insights, which are available in the full report.
The market is valued at US$ 25.5 billion in 2023.
The growth potential of the cancer biopsy market is 18% CAGR through 2033.
The market is estimated to reach US$ 131.4 billion by 2033.
The United States market is expected to expand at a CAGR of 21.4% through 2033.
Tissue biopsies are expected to find greater applications in cancer diagnosis.
1. Executive Summary |Cancer Biopsy Market
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Future Market Insights Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ Billion)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends
4. Market Background
4.1. Market, by Key Countries
4.2. Market Opportunity Assessment (US$ Billion)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors - Relevance & Impact
4.5.1. Top Companies Historical Growth
4.5.2. Growth in Automation, By Country
4.5.3. Patch Management Adoption Rate, By Country
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. Patch Management Market Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment
5. Key Success Factors
5.1. Manufacturers’ Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking
6. Global Market Demand Analysis 2018 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Analysis, 2018 to 2022
6.2. Current and Future Market Projections, 2023 to 2033
6.3. Y-o-Y Growth Trend Analysis
7. Global Market Value Analysis 2018 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Billion) Analysis, 2018 to 2022
7.2. Current and Future Market Value (US$ Billion) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Billion) Analysis By Type, 2018 to 2022
8.3. Current and Future Market Size (US$ Billion) Analysis and Forecast By Type, 2023 to 2033
8.3.1. Tissue Biopsies
8.3.1.1. Needle Biopsies
8.3.1.2. Surgical Biopsies
8.3.2. Liquid Biopsies
8.3.3. Other Types
8.4. Market Attractiveness Analysis By Type
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Billion) Analysis By Product Type, 2018 to 2022
9.3. Current and Future Market Size (US$ Billion) Analysis and Forecast By Product Type, 2023 to 2033
9.3.1. Instruments
9.3.2. Kits and Consumables
9.3.3. Services
9.4. Market Attractiveness Analysis By Product Type
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Billion) Analysis By Application, 2018 to 2022
10.3. Current and Future Market Size (US$ Billion) Analysis and Forecast By Application, 2023 to 2033
10.3.1. Software
10.3.2. Services
10.3.3. Cervical Cancers
10.3.4. Training and Education Services
10.3.5. Prostate Cancers
10.3.6. Blood Cancers
10.3.7. Skin Cancers
10.3.8. Kidney Cancers
10.3.9. Liver Cancers
10.3.10. Pancreatic Cancers
10.3.11. Ovarian Cancers
10.3.12. Other Applications
10.4. Market Attractiveness Analysis By Application
11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
11.1. Introduction
11.2. Historical Market Size (US$ Billion) Analysis By Region, 2018 to 2022
11.3. Current Market Size (US$ Billion) & Analysis and Forecast By Region, 2023 to 2033
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. Asia Pacific
11.3.5. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
12.1. Introduction
12.2. Pricing Analysis
12.3. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
12.4. Market Size (US$ Billion) & Forecast By Market Taxonomy, 2023 to 2033
12.4.1. By Country
12.4.1.1. United States of America
12.4.1.2. Canada
12.4.1.3. Rest of North America
12.4.2. By Type
12.4.3. By Application
12.4.4. By Product Type
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Type
12.5.3. By Application
12.5.4. By Product Type
13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
13.4. Market Size (US$ Billion) & Forecast By Market Taxonomy, 2023 to 2033
13.4.1. By Country
13.4.1.1. Brazil
13.4.1.2. Mexico
13.4.1.3. Rest of Latin America
13.4.2. By Type
13.4.3. By Application
13.4.4. By Product Type
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Type
13.5.3. By Application
13.5.4. By Product Type
14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
14.4. Market Size (US$ Billion) & Forecast By Market Taxonomy, 2023 to 2033
14.4.1. By Country
14.4.1.1. Germany
14.4.1.2. France
14.4.1.3. United Kingdom
14.4.1.4. Italy
14.4.1.5. Spain
14.4.1.6. Netherlands
14.4.1.7. Rest of Europe
14.4.2. By Type
14.4.3. By Application
14.4.4. By Product Type
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Type
14.5.3. By Application
14.5.4. By Product Type
15. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
15.4. Market Size (US$ Billion) & Forecast By Market Taxonomy, 2023 to 2033
15.4.1. By Country
15.4.1.1. China
15.4.1.2. Japan
15.4.1.3. South Korea
15.4.1.4. Rest of Asia Pacific
15.4.2. By Type
15.4.3. By Application
15.4.4. By Product Type
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Type
15.5.3. By Application
15.5.4. By Product Type
16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
16.4. Market Size (US$ Billion) & Forecast By Market Taxonomy, 2023 to 2033
16.4.1. By Country
16.4.1.1. Saudi Arabia
16.4.1.2. South Africa
16.4.1.3. UAE
16.4.1.4. Rest of Middle East and Africa
16.4.2. By Type
16.4.3. By Application
16.4.4. By Product Type
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Type
16.5.3. By Application
16.5.4. By Product Type
17. Key Countries Market Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.1.1. Market Value Proportion Analysis, By Key Countries
17.1.2. Global Vs. Country Growth Comparison
17.2. USA Market Analysis
17.2.1. Value Proportion Analysis by Market Taxonomy
17.2.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.2.2.1. By Type
17.2.2.2. By Application
17.2.2.3. By Product Type
17.3. Canada Market Analysis
17.3.1. Value Proportion Analysis by Market Taxonomy
17.3.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.3.2.1. By Type
17.3.2.2. By Application
17.3.2.3. By Product Type
17.4. Mexico Market Analysis
17.4.1. Value Proportion Analysis by Market Taxonomy
17.4.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.4.2.1. By Type
17.4.2.2. By Application
17.4.2.3. By Product Type
17.5. Brazil Market Analysis
17.5.1. Value Proportion Analysis by Market Taxonomy
17.5.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.5.2.1. By Type
17.5.2.2. By Application
17.5.2.3. By Product Type
17.6. Germany Market Analysis
17.6.1. Value Proportion Analysis by Market Taxonomy
17.6.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.6.2.1. By Type
17.6.2.2. By Application
17.6.2.3. By Product Type
17.7. France Market Analysis
17.7.1. Value Proportion Analysis by Market Taxonomy
17.7.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.7.2.1. By Type
17.7.2.2. By Application
17.7.2.3. By Product Type
17.8. Italy Market Analysis
17.8.1. Value Proportion Analysis by Market Taxonomy
17.8.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.8.2.1. By Type
17.8.2.2. By Application
17.8.2.3. By Product Type
17.9. Spain Market Analysis
17.9.1. Value Proportion Analysis by Market Taxonomy
17.9.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.9.2.1. By Type
17.9.2.2. By Application
17.9.2.3. By Product Type
17.10. United Kingdom Market Analysis
17.10.1. Value Proportion Analysis by Market Taxonomy
17.10.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.10.2.1. By Type
17.10.2.2. By Application
17.10.2.3. By Product Type
17.11. Netherlands Market Analysis
17.11.1. Value Proportion Analysis by Market Taxonomy
17.11.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.11.2.1. By Type
17.11.2.2. By Application
17.11.2.3. By Product Type
17.12. China Market Analysis
17.12.1. Value Proportion Analysis by Market Taxonomy
17.12.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.12.2.1. By Type
17.12.2.2. By Application
17.12.2.3. By Product Type
17.13. Japan Market Analysis
17.13.1. Value Proportion Analysis by Market Taxonomy
17.13.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.13.2.1. By Type
17.13.2.2. By Application
17.13.2.3. By Product Type
17.14. South Korea Market Analysis
17.14.1. Value Proportion Analysis by Market Taxonomy
17.14.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.14.2.1. By Type
17.14.2.2. By Application
17.14.2.3. By Product Type
17.15. Saudi Arabia Market Analysis
17.15.1. Value Proportion Analysis by Market Taxonomy
17.15.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.15.2.1. By Type
17.15.2.2. By Application
17.15.2.3. By Product Type
17.16. South Africa Market Analysis
17.16.1. Value Proportion Analysis by Market Taxonomy
17.16.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.16.2.1. By Type
17.16.2.2. By Application
17.16.2.3. By Product Type
17.17. UAE Market Analysis
17.17.1. Value Proportion Analysis by Market Taxonomy
17.17.2. Value & Analysis and Forecast by Market Taxonomy, 2018 to 2033
17.17.2.1. By Type
17.17.2.2. By Application
17.17.2.3. By Product Type
17.17.3. Competition Landscape and Player Concentration in the Country
18. Market Structure Analysis
18.1. Market Analysis by Tier of Companies
18.2. Market Concentration
18.3. Market Share Analysis of Top Players
18.4. Market Presence Analysis
18.4.1. By Regional footprint of Players
18.4.2. Product footprint by Players
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Competition Deep Dive
19.3.1. Qiagen N.V.
19.3.1.1. Overview
19.3.1.2. Product Portfolio
19.3.1.3. Sales Footprint
19.3.1.4. Strategy Overview
19.3.2. Illumina, Inc.
19.3.2.1. Overview
19.3.2.2. Product Portfolio
19.3.2.3. Sales Footprint
19.3.2.4. Strategy Overview
19.3.3. ANGLE Plc
19.3.3.1. Overview
19.3.3.2. Product Portfolio
19.3.3.3. Sales Footprint
19.3.3.4. Strategy Overview
19.3.4. Becton, Dickinson, and Company
19.3.4.1. Overview
19.3.4.2. Product Portfolio
19.3.4.3. Sales Footprint
19.3.4.4. Strategy Overview
19.3.5. Myriad Genetics
19.3.5.1. Overview
19.3.5.2. Product Portfolio
19.3.5.3. Sales Footprint
19.3.5.4. Strategy Overview
19.3.6. Hologic, Inc.
19.3.6.1. Overview
19.3.6.2. Product Portfolio
19.3.6.3. Sales Footprint
19.3.6.4. Strategy Overview
19.3.7. Biocept, Inc.
19.3.7.1. Overview
19.3.7.2. Product Portfolio
19.3.7.3. Sales Footprint
19.3.7.4. Strategy Overview
19.3.8. Thermo Fisher Scientific, Inc.
19.3.8.1. Overview
19.3.8.2. Product Portfolio
19.3.8.3. Sales Footprint
19.3.8.4. Strategy Overview
19.3.9. Danaher
19.3.9.1. Overview
19.3.9.2. Product Portfolio
19.3.9.3. Sales Footprint
19.3.9.4. Strategy Overview
19.3.10. F. Hoffmann-La Roche Ltd.
19.3.10.1. Overview
19.3.10.2. Product Portfolio
19.3.10.3. Sales Footprint
19.3.10.4. Strategy Overview
19.3.11. Lucence Diagnostics Pte. Ltd.
19.3.11.1. Overview
19.3.11.2. Product Portfolio
19.3.11.3. Sales Footprint
19.3.11.4. Strategy Overview
19.3.12. GRAIL, Inc.
19.3.12.1. Overview
19.3.12.2. Product Portfolio
19.3.12.3. Sales Footprint
19.3.12.4. Strategy Overview
20. Assumptions and Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Cancer Biopsy Market
